How to emerge from the conservatism in clinical research methodology?

Auteurs : Kotecki N, Penel N, Awada A
Année : 2017
Journal : Curr Opin Oncol
Volume : 29(5)
Pages : 400-404

Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue

Auteurs : Kotecki N, Awada A, Bonneterre J, Hebbar M, Adenis A, Cortot AB, Cousin C, Clisant S, Duhamel A, Penel N
Année : 2016
Journal : Pharmaceutical Medicine
Volume : 30(3)
Pages : 143-7

Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better

Auteurs : Awada A, Penel N, Kotecki N
Année : 2016
Journal : TCR
Volume : 5(6)
Pages : s1160-62

Metabolic disorders associated with the use of targeted cancer therapies.

Auteurs : Kotecki N, Penel N, Awada A
Année : 2015
Journal : Curr Opin Oncol
Volume : 27(3)
Pages : 258-66